Topics
cancer
Press Trust of India | London Last Updated at July 4, 2022 20:29 IST
https://mybs.in/2ax0ijM
An Indian-origin woman who was given just months to live a few years ago is celebrating on Monday after doctors say she is showing no evidence of breast cancer following a clinical trial at a UK hospital.
Jasmin David, 51, from Fallowfield in Manchester is now looking forward to celebrating her 25th wedding anniversary in September after the successful National Health Service (NHS) trial.
David's two-year trial at the National Institute for Health and Care Research (NIHR) Manchester Clinical Research Facility (CRF) at Christie NHS Foundation Trust involved an experimental medicine combined with Atezolizumab, an immunotherapy drug administered intravenously which she continues to have every three weeks.
I was 15 months down the line after my initial cancer treatment and had almost forgotten about it, but then the cancer returned, recalls David.
When I was offered the trial, I didn't know if it would work for me, but I thought that at least I could do something to help others and use my body for the next generation. At first, I had many horrible side effects including headaches and spiking temperatures, so I was in hospital over Christmas and quite poorly. Then thankfully I started to respond well to the treatment, she said.
The previously fit and healthy mother of two grown-up children, worked as a clinical lead at a care home for the elderly.
She discovered she had an aggressive triple negative form of breast cancer in November 2017, when she found a lump above the nipple.
She underwent six months of chemotherapy and a mastectomy in April 2018, followed by 15 cycles of radiotherapy which cleared her body of cancer.
Then in October 2019 the cancer returned, and scans showed multiple lesions throughout her body meaning she had a poor prognosis.
The cancer had spread to the lungs, lymph nodes and chest bone and she was given the devastating news that she had less than a year to live. Two months later, and with no other options left, David was offered the opportunity to be part of research by participating in a Phase I clinical trial.
I celebrated my 50th birthday in February 2020 while still in the middle of treatment and not knowing what the future held. Two and a half years ago I thought it was the end and I now feel like I've been reborn, said David.
There is a change in my life after returning from India to see family in April and I have decided to take early retirement and to live my life in gratitude to God and to medical science. My family have been very supportive of this decision. I will be celebrating my 25th wedding anniversary in September. I have so much to look forward to, she said.
My Christian faith helped me a lot on this journey and the prayers and support from family and friends gave me strength to face the challenge, she added. By June 2021, scans showed no measurable cancer cells in her body and she was deemed cancer free. She will remain on treatment until December 2023 but continues to show no evidence of the disease.
We are really pleased that Jasmin has had such a good outcome. At The Christie we are continually testing new drugs and therapies to see if they can benefit more people, said Professor Fiona Thistlethwaite, medical oncologist and clinical director of Manchester CRF at The Christie.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
PREVIOUS STORY
NEXT STORY
Copyrights © 2022 Business Standard Private Ltd. All rights reserved.
Upgrade To Premium Services
Business Standard is happy to inform you of the launch of “Business Standard Premium Services”
As a premium subscriber you get an across device unfettered access to a range of services which include:
Premium Services
In Partnership with 
Dear Guest,
Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.
Enjoy Reading!
Team Business Standard
